Details of Drug-Drug Interaction
| Drug General Information (ID: DDIWSFMI5D) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Trastuzumab | Drug Info | Efalizumab | Drug Info | |||||
| Drug Type | Monoclonal antibody | Monoclonal antibody | |||||||
| Therapeutic Class | Antineoplastics | Immunomodulatory Agents | |||||||
| Mechanism of Trastuzumab-Efalizumab Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive immunosuppressive effects Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Trastuzumab | Efalizumab | |||||||
| Mechanism | Immunosuppressive effects | Immunosuppressive effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Immunosuppressive effects | ||||||||
| Factor Description | Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA. | ||||||||||||||||||

